Cytokinesis is the final step of cell division. Increasing evidence suggests failure of cytokinesis might contribute to the development of cancer. Here, we demonstrate that the serologically defined colon cancer antigen-3 (SDCCAG3) forms a complex with PTPN13, a protein tyrosine phosphatase known to be involved in the regulation of cytokinesis, carcinogenesis and tumor aggressiveness. We show that SDCCAG3 is a novel endosomal protein, primarily localized at the early/recycling endosomal compartment. SDCCAG3 undergoes dynamic localization during cell division with strong accumulation at the midbody during cytokinesis. Overexpression as well as downregulation correlates with the generation of multinucleate cells. Furthermore, we show interaction of SDCCAG3 with the Arf GTPase activating protein GIT1 (G protein-coupled receptor kinase interactor-1). Overexpression of an ArfGAP-negative version of GIT1 also results in an increased number of multinucleate cells suggesting regulation of Arf-mediated vesicular trafficking or signaling via SDCCAG3. Finally, we demonstrate that SDCCAG3 expression levels are elevated in colon cancers. In summary, we have established SDCCAG3 as a novel endosomal protein, which is involved in the regulation of cytokinesis.
INTRODUCTION
Cytokinesis is the last step of cell division leading to the physical separation of the two daughter cells. Cytokinesis requires a tight regulation of cytoskeleton and membrane dynamics and only recently the importance of vesicular trafficking events for this process has been revealed. [1] [2] [3] Impairment of cytokinesis often results in the generation of bi-or multinucleate cells (aneuploidy). Aneuploidy is a hallmark of many cancers and it has been shown that chemically induced tetraploidy 4 or random chromosomal missegregations 5 leading to aneuploidy can promote tumor development.
Previously, we have shown that the protein tyrosine phosphatase PTPN13, a candidate tumor suppressor protein implicated in tumor development and progression, 6, 7 is involved in the regulation of cytokinesis.
8 PTPN13 (aliases are PTPL1, hPTP1e, PTP-Bas and FAP-1; the mouse homolog is named as PTP-BL or here mPTPN13) is a highly modular multi-PDZ domain protein composed of an N-terminal KIND (Kinase non-catalytic C-lobe) domain, followed by an FERM (Four-point-one/Ezrin/Radixin/ Moesin) domain, five PDZ domains and a tyrosine phosphatase domain. 9 PTPN13 is highly expressed in polarized epithelial cells. 10, 11 Given its modular structure PTPN13 serves as a scaffold protein organizing a supramolecular protein complex. There is strong evidence that PTPN13 has a role in tumor development. PTPN13 is a direct transcriptional target of the Ewing's sarcoma family of tumors oncogene, EWS-FLI1, and promotes cell growth and oncogenesis 12 as well as breast cancer aggressiveness. 13 In a search for protein tyrosine phosphatases involved in formation of colon carcinoma, it was demonstrated that PTPN13 is mutated in around 10% of colon carcinomas.
14 PTPN13 negatively regulates the malignant signaling of the receptor tyrosine kinase Her2/Erb2, 15 and the human papillomavirus oncogene E6 directly interacts with and downregulates PTPN13, which leads to anchorage-independent cell growth and increased tumor invasion. 16 Finally, PTPN13 reduces the sensitivity of cells to Fas-ligand induced apoptosis conferring resistance to the Fas apoptosis system in many tumorderived cell lines. [17] [18] [19] [20] Here, we report interaction of PTPN13 with the serologically defined colon cancer antigen-3 (SDCCAG3). SDCCAG3 was identified as an antigen recognized by the serum from colon cancer patients. 21 Human SDCCAG3 is a 45-kDa protein harboring a coiled-coil domain in its C-terminal half but no obvious catalytic activity. Overexpression of a truncated version of SDCCAG3 containing the coiled-coil domain led to reduced surface expression of the tumor necrosis factor receptor-I (TNFR-I) and to resistance toward TNF-induced apoptosis suggesting a potential role of SDCCAG3 in receptor trafficking. 22 In this study, we demonstrate that SDCCAG3 is a novel endosomal protein interacting with the protein tyrosine phosphatase PTPN13 and the ArfGAP GIT1 (G protein-coupled receptor kinase interactor-1). We provide evidence that SDCCAG3 might have a role in the regulation of cytokinesis and show that expression levels of SDCCAG3 are elevated in colon carcinoma. 1 
RESULTS

SDCCAG3 forms a complex with the protein tyrosine phosphatase PTPN13
The protein tyrosine phosphatase PTPN13 is a modular scaffolding protein containing an N-terminal KIND domain followed by a FERM domain and five PDZ domains; a protein tyrosine phosphatase domain is localized at the C-terminus (Figure 1a) . Previously, we have shown that PTPN13 is involved in the regulation of cytokinesis; 8 however, the underlying mechanism is completely unclear. In a yeast two-hybrid screen performed with the FERM domain of mouse PTPN13 (mPTPN13) as bait, we identified the protein SDCCAG3 as a potential binding partner HeLa cells were co-transfected with expression vectors for myc-SDCCAG3 and EGFP-fusion proteins with the FERM domain or the PDZ domains of mPTPN13. Cell lysates were subjected to GFP-Trap and protein complexes were separated by SDS-PAGE, transferred onto nitrocellulose and detected using an anti-myc (upper panel) or anti-GFP antibody (lower panel). (d) SDCCAG3 is a phosphoprotein. Myc-SDCCAG3 was purified from HeLa cells, transfected with a myc-SDCCAG3 expression vector, using anti-myc agarose. Purified myc-SDCCAG3 was incubated with or without calf intestinal phosphatase (CIP) and separated by SDS-PAGE. Proteins were transferred onto nitrocellulose and developed using an anti-myc antibody. (e) Interaction of endogenous PTPN13 with EGFP-SDCCAG3. HeLa cells were transfected with an expression vector for SDCCAG3 fused to EGFP. SDCCAG3 and associated proteins were collected using corresponding cell lysates and GFP-Trap. Protein complexes were separated by SDS-PAGE, transferred onto nitrocellulose and detected using an anti-GFP (lower panel) or an anti-PTPN13 antibody (upper panel). (Figure 1b) . The interaction between the FERM domain of mPTPN13 and SDCCAG3 is highly specific because no interaction could be detected between SDCCAG3 and the FERM domain of the PTPN13-related protein FRMPD2 or the PDZ1-5 domains of mPTPN13 ( Figure 1b ). SDCCAG3 is a sparsely characterized protein of 45 kDa containing a coiled-coil domain but no obvious catalytic activity. It has been suggested that SDCCAG3 regulates cell surface levels of the TNFR-I. 22 Because several studies demonstrated that PTPN13 also regulates cell surface expression levels of the Fas receptor, which is a member of the TNFR family, 19, 20, 23 SDCCAG3 is a promising candidate for a functionally relevant novel PTPN13 binding protein. GFP-Trap pulldown experiments using a fusion protein of EGFP with the FERM domain of mPTPN13 and myc-SDCCAG3 confirmed interaction between the FERM domain of mPTPN13 and SDCCAG3. No interaction could be observed using a fusion protein of EGFP with the PDZ1-5 domains of mPTPN13 and myc-SDCCAG3 (Figure 1c) . We noticed that SDCCAG3 appears in several bands in immunoblots suggesting degradation, alternative splicing or post-translational modification of SDCCAG3. Preincubation of immunoprecipitated myc-SDCCAG3 with calf intestinal alkaline phosphatase significantly increased the mobility of myc-SDCCAG3 while significantly decreasing the number of corresponding bands in SDS-PAGE suggesting extensive phosphorylation of myc-SDCCAG3 (Figure 1d ). Phosphorylation of myc-SDCCAG3 was confirmed using mass spectrometry (data not shown).
Finally, to demonstrate interaction of full-length PTPN13 and full-length SDCCAG3 in cells, we transfected HeLa cells with an (e) SDCCAG3-pulldown experiment. Cos7 cells were transfected with myc-SDCCAG3 and indicated EGFP-fused expression constructs of different FERM domain mutations, previously shown to inhibit PtdIns(4,5)P 2 binding. Cells were lysed and GFP-Trap pulldown was performed as described before. (f ) HeLa cells were grown on coverslips and transfected with an expression construct for the N-terminal part (LN) of mPTPN13 fused to EGFP. Cells were fixed and stained for endogenous SDCCAG3 (red) and tubulin (blue), and dividing cells were analyzed using confocal microscopy. Scale bars represent 10 mm.
Serologically defined colon cancer antigen-3 interacts with PTPN13 N Hagemann et al expression construct for EGFP-SDCCAG3 and performed a pulldown experiment using GFP-Trap. Endogenous PTPN13 could be detected in pulldown experiments using EGFP-SDCCAG3 but not in corresponding experiments using EGFP, indicating that fulllength PTPN13 and SDCCAG3 can form a complex in cells (Figure 1e ).
Mapping of the SDCCAG3/FERM binding site To identify the binding region of the mPTPN13 FERM domain within SDCCAG3, we performed a series of mapping experiments using the yeast two-hybrid system (Supplementary Figure S1) and GFP-Trap pulldown experiments. We mapped the binding region to amino acids 150-175 in the N-terminal region of SDCCAG3. A corresponding deletion construct of SDCCAG3 lacking amino acids 150-175 failed to interact with mPTPN13 ( Figure 2a ). Within this 25 amino-acid region we identified two point mutations (P167A; E171A), which led to complete abolishment of the mPTPN13/ SDCCAG3 interaction, whereas mutation of tryptophan 161 (W161A) did not affect the interaction (Figures 2a and b) . The FERM domain of PTPN13 can also bind to phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ) and this binding is important for plasma membrane localization of PTPN13. The general structure of the FERM domain consists of three subdomains (A-C) and subdomain A and subdomain C are involved in PtdIns(4,5)P 2 binding. Individual mutations in subdomain A (KN1) and C (KN2) reduce binding to PtdIns(4,5)P 2 but only a combination of mutations in subdomain A and C (KN1-2) led to a complete loss of PtdIns(4,5)P 2 binding and plasma membrane localization (Figures 2c and d and Bompard et al. 24 ). We tested these mutations known to abolish PtdIns(4,5)P 2 interaction with respect to binding capacity to SDCCAG3 and demonstrate that KN1 does not affect SDCCAG3 binding. However, KN2 leads to a reduction and a combination of both (KN1-2) to a complete abolishment of FERM domain binding to SDCCAG3 (Figure 2e ). We conclude that SDCCAG3 and PtdIns(4,5)P 2 share an overlapping binding site in the FERM domain of PTPN13.
SDCCAG3 and PTPN13 colocalize at the midbody Previously, we have shown that the protein tyrosine phosphatase PTPN13 displays a dynamic localization during cell division and that it is involved in the regulation of cytokinesis. In particular, strong accumulation at the midbody could be observed during cytokinesis. 8 Immunofluorescence analysis also revealed strong accumulation of endogenous SDCCAG3 at the midbody, similarly to endogenous PTPN13. In addition, endogenous SDCCAG3 colocalized with an EGFP-fusion protein of the mPTPN13-Nterminus ( Figure 2f ). We have shown before that PTPN13 localization to the midbody is mediated by its N-terminus. 8 Unfortunately, we do not have an anti-PTPN13 antibody suitable for double immunofluorescene with our rabbit SDCCAG3 antibody. Serologically defined colon cancer antigen-3 interacts with PTPN13 N Hagemann et al SDCCAG3 is localized to endosomes and shows dynamic localization during cell division The midbody localization of SDCCAG3 ( Figure 2f ) prompted us to analyze the subcellular localization of SDCCAG3 during cell division. We observed a punctuate cytosolic pattern for SDCCAG3 from interphase to metaphase. These dots start to accumulate during late anaphase at the cleavage furrow. At telophase clear accumulation at the intercellular bridge and the polar regions of the two cells is visible. Finally, SDCCAG3 becomes part of the midbody at the intercellular bridge as shown by colocalization with beta-tubulin ( Figure 3 ). The specificity of our SDCCAG3 antibody was confirmed by lack of staining of HeLa cells expressing specific shRNA (Supplementary Figure S2) . The punctuate pattern of SDCCAG3 and its dynamic localization during cell division is similar to the appearance and behavior of early or recycling endosomes. Thus, we analyzed whether SDCCAG3 might localize to endosomes. Using double-immunofluorescence analysis, we observed significant colocalization of endogenous SDCCAG3 with the transferrin receptor, a marker protein of early/recycling endosomes. Similar colocalization of SDCCAG3 was observed with the early endosome antigen 1 (EEA1), a marker protein for early endosomes ( Figure 4 ). Careful inspection of the immunofluorescence images of EEA1 and SDCCAG3 revealed that individual EEA1-positive and SDCCAG3-positive puncta show the same distribution pattern but only partial overlap suggesting occupation of different endosomal subdomains. No colocalization could be observed with lysosomes as revealed by the lysosomal marker protein Lamp-1 or with the late endosomal marker EGFP-Rab9 (Figure 4 ). In addition, we analyzed colocalization of SDCCAG3 with Rab5, the Golgi-marker 58K, the MHC (major histocompatibility complex) class I antigen, and with clathrin heavy chain. We only observed significant colocalization with Rab5 and occasionally with clathrin heavy chain (Supplementary Figure S3) . In summary, we found SDCCAG3 primarily associated with the endosomal compartment, in particular with early/recycling endosomes. SDCCAG3 is involved in the regulation of cytokinesis Motivated by the dynamic localization of SDCCAG3 during cell division and the crucial role of endosome dynamics during cytokinesis, we have analyzed a potential role of SDCCAG3 in the regulation of cytokinesis. Overexpression of myc-SDCCAG3 in HeLa cells correlates with a significantly increased number of multinucleate cells (15.6% for myc-SDCCAG3 transfected cells versus 2% for mock-transfected cells) (Figure 5a ; Supplementary Figure S4a ). Similar numbers of multinucleate cells were observed after overexpression of EGFP-PTPN13 (13.8%), in line with a previous report. 8 In addition, overexpression of a myc-SDCCAG3 deletion variant (D amino acids 150-175) unable to interact with mPTPN13, correlates with significantly less multinucleate cells (6.7%) than wild-type myc-SDCCAG3, suggesting that interaction capacity with mPTPN13 may contribute to the effect observed by overexpression of SDCCAG3 (Figure 5a ). Similar results were found for cell lines HCT116 (colon cancer derived), HEK293 (human embryonic kidney) and NIH3T3 (mouse embryonic fibroblasts) overexpressing myc-or EGFP-SDCCAG3 (Figure 5b ; Supplementary  Figures S4b and c) . To address the role of endogenous SDCCAG3 in cytokinesis, we downregulated its expression level via shRNA. SDCCAG3 shRNA was validated by transient transfection followed by western blotting for endogenous SDCCAG3 (Figure 5c , upper panel). After downregulation of SDCCAG3 we observed a significant higher number of multinucleate cells (6.5% versus 2.5% using a scrambled shRNA construct) (Figures 5d  and e) . A similar increased number of multinucleate cells could further be observed using a PTPN13-specific shRNA (7.2%) ( Figure 5c , lower panel; Figure 5e ). In contrast, no increase in the number of multinucleate cells could be detected after transfection of a scrambled control shRNA. Interestingly, simultaneous transfection of shRNA directed to SDCCAG3 together with an shRNA directed to PTPN13 did not further increase the number of multinucleate cells, suggesting SDCCAG3 and PTPN13 to act along the same pathway (Figure 5e ). In addition, we confirmed our results independent from HeLa cells in HCT116 cells and in HEK293 cells and also observed an increased number of multinucleate cells after shRNA-mediated downregulation of SDCCAG3 (Figure 5f; Supplementary Figure S4d) . Finally, we revealed that siRNA-mediated downregulation of SDCCAG3 correlates with significantly decreased cell proliferation in HeLa cells (Figure 5g ). SDCCAG3 interacts with the Arf GTPase activating protein GIT1 SDCCAG3 consists of a C-terminal coiled-coil domain but does not have any obvious catalytic activity and thus might serve as an adapter protein. In a large scale yeast two-hybrid screen, the ArfGAP GIT1 was identified as a potential interacting protein for SDCCAG3; however, this potential interaction was not further analyzed. 25 To establish independent evidence for an interaction of SDCCAG3 and GIT1, we performed a pulldown experiment using GST-SDCCAG3 and mouse brain lysate. GIT1 was clearly detected in pulldown experiments using GST-SDCCAG3 but not in corresponding experiments using GST alone (Figure 6a ). To test whether GIT1 and SDCCAG3 interaction is direct, both proteins were purified and recombinant proteins were incubated with each other; binding was determined by pulldown analysis followed by western blotting. GST-SDCCAG3 was able to interact with Histagged GIT1 while GST alone did not show any binding to Histagged GIT1, supporting direct interaction of SDCCAG3 with GIT1 ( Figure 6b ). Using GST-pulldown experiments, we identified two binding sites for SDCCAG3 within GIT1, one in the N-terminal part and the other in the C-terminal part. Both interactions are mediated by the N-terminal part of SDCCAG3 (Supplementary Figure S5a) . Subsequent pulldown experiments further mapped the first binding site to the GIT1 ArfGAP domain, whereas the second binding site comprises the coiled-coil domain plus the region between the coiled-coil domain and the PBS domain ( Supplementary Figures S5b and c) . Interestingly, an N-terminal SDCCAG3 construct (D150-175) lacking the binding site for the FERM domain can still bind to the GIT1 ArfGAP domain, indicating that the two binding sites of SDCCAG3 for the FERM domain and for the GAP domain do not overlap ( Figure 6c) ; thus, opening the possibility of a trimeric complex of PTPN13, SDCCAG3 and GIT1. We could observe formation of such a trimeric complex composed of EGFP-mPTPN13-FERM, myc-SDCCAG3 and endogenous GIT1 using GFP-Trap pulldown experiments (Figure 6d) . Figure 6e shows an overview of the identified binding regions in SDCCAG3 and GIT1. PTPN13 and GIT1 have been reported before to localize at centrosomes. 8, 26 Using confocal triple-immunofluorescence analysis in HCT116 cells we found accumulation of SDCCAG3-positive puncta at the centrosomal area, which partially overlap with GIT1 localized to centrosomes (Figure 6f) . Moreover, SDCCAG3 and GIT1 colocalized in HeLa cells at enlarged vesicular structures after epidermal growth factor treatment in the cell periphery (Supplementary Figure S5e) .
Overexpression of a GTPase activating negative version of GIT1 correlates with an increased number of multinucleate cells GIT1 exerts GAP activity to Arf6 and Arf6-regulated membrane trafficking has an important role in cytokinesis; therefore, we analyzed whether overexpression of GIT1 shows any defects in cytokinesis leading to multinucleate cells. We could not detect any increase in the number of multinucleate cells after transfection of myc-tagged wild-type GIT1 compared with mock transfected cells; in contrast, overexpression of an ArfGAP-negative GIT1-variant (R39A) correlates with an increased number of multinucleate cells (Figures 7a and b) . Next, we analyzed the role of endogenous GIT1 by shRNA-mediated downregulation (Figures 7c  and d) . We observed a threefold increase in the number of multinucleate cells after downregulation of GIT1. This was Serologically defined colon cancer antigen-3 interacts with PTPN13 N Hagemann et al Serologically defined colon cancer antigen-3 interacts with PTPN13 N Hagemann et al comparable to the effect observed after downregulation of SDCCAG3. Moreover, double transfection with shRNA for SDCCAG3 or shRNA for PTPN13 did not further increase the number of multinucleate cells, suggesting that all three proteins PTPN13, SDCCAG3 and GIT1 might act along the same pathway (Figure 7d) . Finally, to establish evidence whether interaction with GIT1 is important for the effect of SDCCAG3 overexpression on multinuclearity we applied an SDCCAG3 construct (SDCCAG3D1- 
SDCCAG3 expression level is increased in colon cancer tissue
Having established that SDCCAG3 contributes to the regulation of cytokinesis and given that aneuploidy might be involved in cancer formation, we compared the expression level of SDCCAG3 protein in colon cancer tissue with matched normal tissue samples by immunohistochemistry (Supplementary Figure S6; Figure 8 ). In total, we compared 34 tissue sample pairs. From these 34 sample pairs, 31 pairs showed higher SDCCAG3 expression in the cancer sample compared with the corresponding control sample (Figure 8a ). Moreover, dividing these 68 individual samples into groups of weak, high and strong relative staining intensity for SDCCAG3, the cancer tissue samples showed a clear enrichment in the group of strong staining intensity (Figure 8b ). We also analyzed our tissue array data according to gender, age of the patients as well as according to tumor stage but could not identify any obvious correlation (Supplementary Figure S7) . In summary, these results demonstrate an increased expression level of SDCCAG3 in colon cancer tissue compared with normal tissue.
DISCUSSION
Here, we report the interaction of PTPN13, a protein tyrosine phosphatase implicated in tumor development and progression, with the SDCCAG3 protein. Interaction of SDCCAG3 with PTPN13 is mediated via the FERM domain of PTPN13 and via the N-terminus of SDCCAG3. Previously, it has been shown that the FERM domain of PTPN13 interacts with PtdIns(4,5)P 2 and that this interaction contributes to plasma membrane localization of PTPN13. 24 To our knowledge, SDCCAG3 is the first direct protein interaction partner for the FERM domain of PTPN13. Our finding is in line with the fact that FERM domains can function as phospholipid binding domains as well as protein/protein interaction domains. 27, 28 Previously, cytosolic localization of SDCCAG3 as well as localization to intracellular structures has been observed using transfected SDCCAG3 constructs. 22 Here, we demonstrate that endogenous SDCCAG3 localizes to early/recycling endosomes in HeLa cells as revealed by colocalization with EEA1 as well as with the transferrin receptor. We observed some cytosolic staining as well. The localization of endogenous SDCCAG3 to early/recycling endosomes suggests a possible role for SDCCAG3 in vesicular trafficking. Interestingly, overexpression of the coiled-coil domain of SDCCAG3 correlates with reduced surface expression levels of the TNFR and it has been suggested that SDCCAG3 has a role in trafficking of the TNFR to the plasma membrane. 22 Our finding of SDCCAG3 localization at early/recycling endosomes opens the possibility that SDCCAG3 could be involved in receptor recycling and thus regulates surface expression levels of the TNFR. Similarly to SDCCAG3, PTPN13 is also known to regulate cell surface expression levels of receptors. 19, 20 Great attention has been drawn to PTPN13 because of its potential to regulate the sensitivity of several tumor-derived cell lines to Fas-induced apoptosis. 17, 29 It was shown that the cell surface expression level of the Fas receptor is reduced with increasing expression levels of PTPN13 whereas total Fas receptor expression is not affected. 20, 29 The mechanism how PTPN13 expression regulates the surface expression level of the Fas receptor is unclear; however, given here the established interaction of PTPN13 with SDCCAG3 it is likely that a PTPN13/SDCCAG3 complex is involved in Fas receptor trafficking. A potential role of SDCCAG3 in receptor recycling is also supported by its interaction with GIT1. GIT1 exerts GAP activity to Arf6 (and Arf1), a well-known player in endocytosis and recycling. 30 Indeed, GIT1 has been shown before to be important for basolateral recycling of the thyrotropin receptor in epithelial cells. 31 Here, we show that SDCCAG3 becomes part of the midbody at the end of cytokinesis. PTPN13 also localizes to the midbody and this localization is mediated via an alternatively spliced N-terminus. 8 However, midbody localization of SDCCAG3 does not depend on PTPN13 since downregulation of PTPN13 does not affect localization of SDCCAG3 at the midbody (Supplementary Figure  S8) . Overexpression or downregulation of SDCCAG3 correlates with an increased number of multinucleate cells, suggesting SDCCAG3 to be involved in the regulation of cytokinesis. Simultaneous downregulation of PTPN13 and SDCCAG3 does not further increase the number of multinucleate cells, supporting the idea that PTPN13 and SDCCAG3 act along the same pathway. PTPN13 itself has been implicated in the regulation of cytokinesis in previous studies. Furthermore, the Rho-dependent protein kinase PRK2, which is also a specific binding partner for PTPN13, has been shown to regulate the entry into mitosis as well as the exit from cytokinesis resulting in decreased cell proliferation. 8, 32, 33 Interestingly, we also observed decreased cell proliferation after downregulation of SDCCAG3 in HeLa cells. Thus, PTPN13 might organize a protein complex, which also includes SDCCAG3, regulating certain aspects of cell division, in particular of cytokinesis.
How SDCCAG3 contributes to the regulation of cytokinesis is currently unclear; however, increasing evidence suggests that Serologically defined colon cancer antigen-3 interacts with PTPN13 N Hagemann et al Arf6-regulated endocytic trafficking has an important role in delivering membrane and cargo to sites of division. 34, 35 Here, we show interaction of SDCCAG3 with the ArfGAP GIT1 and demonstrate that overexpression of an ArfGAP inactive GIT1 mutant as well as downregulation of GIT1 also correlates with an increased number of multinucleate cells suggesting Arf-regulated processes to be important for SDCCAG3 function. The G-protein Arf6, a substrate of GIT1, has been shown to have a crucial role in cytokinesis. Arf6 localizes to the cleavage furrow and midbody during cell division. Moreover, depletion of Arf6 leads to incomplete cytokinesis. 36 Arf6 regulates trafficking of recycling endosomes in and out of the intercellular bridge. 37 However, we were not able to detect an accumulation of GIT1 in the intercellular bridge or at the midbody (data not shown), making it unlikely that GIT1 regulates Arf6 directly at the intercellular bridge. However, GIT1 and SDCCAG3 partially colocalize at the centrosomal area. Previously, we have already shown that PTPN13 also localizes at centrosomes. Thus, GIT1 could have a role in the release of endosomes from the centrosomal area at late anaphase followed by their subsequent transport to the intercellular bridge. In addition, GIT1 might act at other sites influencing cytokinesis. It was shown recently that Arf6 also regulates the loading of the G-protein Rab35 into the endocytic pathway at the level of clathrin-coated pits. 38 This results in lower presence of Rab35 at the intercellular bridge with concomitant cytokinesis defects. 39 In fact, it has been shown that GIT1 also has an important role in regulation of receptor endocytosis through clathrin-coated pits and that this function depends on its ArfGAP activity. 40, 41 However, further experiments are needed to fully understand the role of SDCCAG3 and GIT1 in cytokinesis.
Defects in cytokinesis lead to bi-or multinucleate cells that can lead to chromosome instability and tumorigenesis.
4,42,43 SDCCAG3 was first identified as an antigen recognized by serum from colon cancer patients, 21 but it is unclear whether SDCCAG3 is involved in development or progression of colon cancers. We show here that expression levels of SDCCAG3 are elevated in colon cancer tissues and that elevating the expression level of SDCCAG3 can lead to the formation of multinucleate cells. Thus, it will be important to further analyze the molecular role of SDCCAG3 and its potential contribution to tumor formation.
MATERIALS AND METHODS
DNA constructs
Full-length SDCCAG3 cDNA (NM_006643) was purchased from Origene (Rockville, MD, USA) and subcloned using standard PCR techniques. Fulllength GIT1 was cloned from human brain Matchmaker cDNA library (Clontech, Saint-Germain-en-Laye, France). Cloning vectors were pEGFP-C1 (Clontech) or pcDNA3 vector (Invitrogen, Darmstadt, Germany) harboring an N-terminal myc-, EGFP-or Flag-tag. GST-fusion proteins were generated using the pGEX-6P-1 vector (GE Healthcare, Munich, Germany). Full-length GIT1 containing a C-terminal 6 Â His-tag was subcloned into the pVL1392 vector (BD Biosciences, Heidelberg, Germany) for purification from insect cells. Plasmids containing cDNA of full-length mouse PTPN13 have been described earlier. 8 Mutagenesis of PtdIns(4,5)P 2 binding sites was performed as described earlier. 24 Plasmids containing shRNA against SDCCAG3 or GIT1 were generated by cloning the target sequences 5 0 -TAC GACGCACTGAAAGATGAA-3 0 for SDCCAG3 or 5 0 -GACCTCAGCAAGC AACTACAC-3 0 for GIT1 into the pGFP-V-RS vector (Origene). PTPN13 shRNA and scrambled control shRNA in pGFP-V-RS were purchased from Origene. siRNA against SDCCAG3 and controls were purchased from Qiagen (Hilden, Germany).
Antibodies
Rabbit-anti-SDCCAG3 (Proteintech, Manchester, UK), rabbit-anti-PTPN13 (H-300; Santa Cruz, Heidelberg, Germany), mouse-anti-transferrin receptor (Fitzgerald Industries, Acton, MA, USA), mouse-anti-EEA1 (BD Biosciences), mouse-anti-lamp1 (CD107a; BD Biosciences), mouse-anti-acetylatedalpha-tubulin (Sigma-Aldrich, Munich, Germany), mouse-anti-GIT1 (BD Bio-sciences), mouse-anti-Rab5 (BD Biosciences), mouse-anti-MHC class I (Sigma-Aldrich), mouse-anti-Golgi58K protein (Sigma-Aldrich), mouse-antiClathrin-heavy-chain (BD Biosciences), mouse-anti-Pericentrin (Abcam, Cambridge, UK), rabbit-anti-EGFP (Invitrogen), rabbit-anti-myc (A-14; Santa Cruz), mouse-anti-myc (Gentaur, Kampenhout, Belgium), mouse-anti-Flag (Sigma-Aldrich) and anti-rabbit-or anti-mouse-Alexa-Fluor-488 and -555 (Invitrogen) were purchased from commercial sources. Polyclonal antibody against SDCCAG3 was generated by immunizing rabbits with a glutathione-S-transferase-fusion protein of full-length SDCCAG3.
Cell culture, transfection and cell proliferation HeLa, Cos7, HEK293, NIH3T3 or HCT116 cells were cultured in appropriate medium in 10% CO 2 atmosphere. Cells were transfected with Polyfect (Qiagen), Lipofectamine (Invitrogen) or Fugene 6 (Roche, Mannheim, Germany) according to manufacturer's protocol. Localization and western blot analysis, if not otherwise indicated, were performed 48 h after transfection. SF21 insect cells were purchased from BD Biosciences and maintained in BD BaculoGold Max-XP insect cell medium. Cell proliferation/viability was determined using MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) (Sigma-Aldrich) according to manufacturer's instructions.
Protein expression and purification GST-fusion proteins were expressed in E. coli BL21 DE3 codon plus cells for 4 h at 18 1C. Cells were lysed in 1 Â PBS, 0.5% Triton X-100 using a Microfluidizer (Microfluidics, Newton, MA, USA). Purification of proteins was performed using glutathione agarose 4B (Macherey Nagel, Dueren, Germany) according to manufacturer's protocol. For purification of proteins from insect cell lysates Ni-NTA-agarose (Qiagen) was used according to manufacturer's protocol.
Protein interaction experiments and immunoblotting
Cells were lysed in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 , 1mM EDTA, 10% glycerol, 1% Triton X-100). For GST-pulldown assays, equal amounts of GST-fusion proteins bound to glutathione agarose 4B (Macherey Nagel) were incubated for 3 h at 4 1C with lysates of HeLa or Cos7 cells transfected with the relevant expression constructs. After three washing steps with lysis buffer, bound proteins were eluted in Laemmli buffer at 95 1C and separated by SDS-PAGE.
For GFP-Trap pulldown, cell lysates were incubated for 2 h with GFPTrap_A (ChromoTek, Planegg-Martinsried, Germany) at 4 1C. Washing and elution steps were carried out as described above. Proteins were transferred onto nitrocellulose membrane, incubated with the relevant antibodies and detected by SuperSignal Chemiluminescent Substrate (Fisher Scientific, Rockford, IL, USA). The Matchmaker GAL4 yeast twohybrid system I (Clontech) was used according to manufacturer's protocol.
Immunostaining and microscopy
HeLa or HCT116 cells grown on coverslips were fixed in 1 Â PBS containing 4% paraformaldehyde. Cells were permeabilized with 0.5% Triton X-100 and blocked with 2% BSA. Coverslips were incubated with the relevant antibodies for 1 h at room temperature followed by extensive washing with 1 Â PBS and mounted on glass slides using Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA, USA). Fluorescence was monitored with an Olympus IX52 inverted microscope. Confocal images were taken with a Leica TCS SP2 Laser Scanning Spectral Confocal Microscope (Leica Microsystems GmbH, Wetzlar, Germany).
Tissue array and immunohistochemistry
Intensity of SDCCAG3 expression in colon cancer was analyzed using a tissue array containing matched tumor and adjacent normal colon tissue (US Biomax, Inc, Rockville, MD, USA; CO-801). Immunohistochemistry was performed using the Vectastain ABC system with diaminobenzidine (DAB; Vector Laboratories) according to manufacturer's protocol. Staining intensity of spots with specific staining of SDCCAG3 was quantified using TINA densitometric analysis software.
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